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Abstract. Poly(adenosine diphosphate-ribose) polymerase 
(PARP)-1 is the prototypical PARP enzyme well known for 
its role in DNA repair and as a pro‑inflammatory protein. 
Since PARP1 is an important co-factor of several other 
pro‑inflammatory proteins, in the present study the possible 
changes in microbial flora of PARP1 knockout mice were 
investigated. Samples from the duodenum, cecum and feces 
from wild type and PARP1 knockout C57BL/6J male mice 
were collected and 16S ribosomal RNA genes were sequenced. 
Based on the sequencing results, the microbiome and compared 
samples throughout the lower part of the gastrointestinal 
system were reconstructed. The present results demonstrated 
that the lack of PARP1 enzyme only disturbed the microbial 
flora of the duodenum, where the biodiversity increased in 
the knockout animals on the species level but decreased on 
the order level. The most prominent change was the over-
whelming abundance of the family Porphyromonadaceae in 
the duodenum of PARP1‑/‑ animals, which disappeared in the 
cecum and feces where families were spread out more evenly 
than in the wild type animals. The findings of the present study 
may improve current understanding of the role of PARP1 in 
chronic inflammatory diseases.
Introduction
Poly[adenosine diphosphate (ADP)-ribose] (PAR) polymerase 
(PARP)-1 is the member of the PARP family that is consid-
ered to be the ‘prototypical’ PARP enzyme (1). PARP1 can be 
activated by DNA strand breaks and a set of posttranslational 
modifications [previously reviewed in (2)]. Active PARP1 
cleaves aldehyde dehydrogenase into nicotinamide and 
ADP-ribose (ADPR), and forms ADPR polymers, also known 
as PAR, on different acceptor proteins (3,4). PAR chains can 
modify the function of the acceptors, enabling PAR‑mediated 
regulation of protein function. PARP1 is responsible for >80% 
of all cellular PARP activities (5,6).
PARP1 is widely recognized as a pro-inflammatory 
protein in T helper1‑mediated pathologies [previously 
reviewed in (7‑9)]. The pro‑inflammatory properties of 
PARP1 have numerous molecular roots. Firstly, PARP1 is a 
vital positive co‑factor of several pro‑inflammatory transcrip-
tion factors [previously reviewed in (7)], of which the first to 
be identified was nuclear factor‑κB (NF‑κB) (10). In addition, 
PARP‑mediated epigenetic changes also contribute to the 
pro‑inflammatory transcriptional properties of PARP1 (11). 
The induction of these transcription factors facilitates the 
production of pro‑inflammatory chemokines, cytokines and 
lipid mediators (7,11). These mediators in turn facilitate the 
chemotaxis of immune cells and also have a pivotal role in 
their activation (12,13). Adhesion factors (such as intercellular 
adhesion molecule 1 and vascular cell adhesion molecule 1) 
that help immune cells enter the site of inflammation are also 
expressed in a PARP1‑dependent manner (14). Finally, there 
are other factors, including inducible nitric oxide synthase, 
cyclooxygenase-2 and certain matrix metalloproteinases that 
are activated in a PARP1‑dependent manner as well (15,16). 
Taken together, immune cell activation, infiltration, cell migra-
tion and oxidative/nitrosative stress are PARP1‑dependent. 
Notably, the administration of PARP inhibitors to humans 
also has an anti‑inflammatory effect (17).
Recent advances in sequencing technology have largely 
increased current knowledge on the composition of the 
microflora (the collective microfloral genome often referred 
to as the microbiome) in various regions of the human 
body (18‑22). Sequencing‑based determination of the micro-
biome not only revealed novel bacterial species and enabled 
the study of the microflora, but also revealed that bodily cavi-
ties (such as lower airways), previously thought to be sterile, 
do contain bacteria in low numbers (18‑22). Furthermore, 
these studies have shed light on the interactions between the 
host and the microbiome. Microbes produce metabolites that 
enter the systemic circulation, and can affect the cells of the 
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host (23‑29) and interact directly with the components of the 
innate immune system (30‑32). In turn, the host influences 
the microbial communities through the immune system, 
feeding behavior and personal hygiene (18). Changes in 
the composition of the microbiome have been associated 
with particular diseases, including metabolic diseases, 
autism and cancer, where the reduction in the diversity of 
the microbiome frequently coincides with the onset of the 
disease (33).
The molecular determinants of the interaction between 
the host's immune system and the microbiome are largely 
unknown. Previous studies have revealed the role of the innate 
immune system, more precisely the Toll‑like receptor (TLR) 
family (30,31,34,35). As PARP1 modulates the TLR‑mediated 
signaling (32,36‑40), the present study was performed to 
investigate the changes in the microbiome upon the deletion 
of PARP1.
Materials and methods
Animals. PARP1 knockout mice with a C57BL/6J back-
ground were used (41), and were generated in Het‑to‑Het 
breeding. A total of 6 mice were housed in each cage (stan-
dard block shape 365x207x140 mm, surface 530 cm2; 1284 L 
Eurostandard Type II. L from Techniplast) with Lignocel 
Select Fine (J. Rettenmaierund Söhne, Germany) as bedding. 
Mice were housed under a 12 h light/dark cycle at 22±1˚C. 
Mice had ad libitum access to food and water (sterilized tap 
water). The animal facility was overseen by a veterinarian. 
Male mice (20 animals, 8‑12 weeks old, 22‑26 g body weight) 
were randomly selected from a larger pool of mice bred at 
the Animal Facility of the University of Debrecen (Debrecen, 
Hungary). Randomization between groups was not possible 
since group assignment was based on genotypes (n=20, 10 
per experimental group). Animals were fasted 16 h prior to 
sampling to exclude the effect of potentially different eating 
periods and ingested food quantities. Following this, fresh 
fecal samples were collected and stored immediately in 
liquid nitrogen. Subsequently, animals were sacrificed by 
cervical dislocation. Subsequently the initial 15 mm segment 
of the duodenum and ~1/3 of the cecum was removed. Both 
intestinal samples in addition to a freshly collected fecal 
pellet were rapidly frozen in liquid nitrogen immediately 
following removal. For long term storage samples were kept 
at ‑80˚C (41). All animal experiments were approved by the 
local and national ethical board of the University of Debrecen 
(reg. 1/2015/DEMÁB).
DNA isolation and sequencing. Total DNA was isolated form 
each sample using the DNeasy PowerSoil kit according to the 
manufacturer's protocol (cat. no. 12888‑100; Qiagen GmbH, 
Hilden, Germany). Subsequently identical amounts of DNA 
from each sample within the groups were pooled; the use of 
identical quantities of DNA ensures that each sample contrib-
utes equally to the abundance. From the pooled samples 16S 
ribosomal RNA genes were amplified and sequenced. Samples 
were assessed for quality and potential contaminants on a 1.5% 
agarose gel. DNA isolation and sequencing were performed 
by UD-GenoMed as a commercial service (UD-GenoMed, 
Debrecen, Hungary).
Analysis of the microbiome. Sequence fragments were 
uploaded to the metagenomics RAST server, MG‑RAST 
(v4.0, metagenomics.anl.gov/) where paired end joining and 
microbiome reconstruction was performed (42). Subsequent 
analysis was performed with a specialized standalone software 
Taxamat (v1.04), which is freely available at www.taxamat.
com. Using Taxamat, data representing food contaminants 
and host DNA (Viridiplantae and Metazoa) was removed. To 
produce the sequencing depth of each sample to a comparable 
level, data were downsampled so that samples with higher 
abundance matched the samples with the lowest abundance 
values. Source files for the sequencing raw and the curated 
data can be found at www.ncbi.nlm.nih.gov/bioproject/411773 
(NCBI Bioproject PRJNA411773).
Statistical analysis. Diversity profiles were created using 
Palaeontological Statistics (PAST) (43). Diversity indices 
were calculated using PAST and Taxamat (www.taxamat.
com). When comparing diversity profiles, the curve data 
points were downsampled to eight evenly distributed 
values over the whole range and statistical significance 
was determined using two tailed Student's t‑test for paired 
samples. Family and order distributions across samples were 
compared using the ‘prop.test’ function (www.rdocumenta-
tion.org/packages/mosaic/versions/1.1.1/topics/prop.test) in 
RStudio (version 0.99.484; www.rstudio.com) (44,45).
Results
As a first step, changes to microbial diversity were assessed by 
comparing the gut samples of the PARP1+/+ and PARP1‑/‑ mice. 
When comparing diversity indices, the main pitfall is the arbi-
trary choice of the used index. To avoid this issue diversity 
profiles were plotted in addition to comparing individual 
indices (Fig. 1). These curves use the parameter (α) dependent 
exponent of the Renyi index (46). This function returns the 
number of taxa at α=0, a number proportional to the Shannon 
index at α=1 and a Simpson‑like index at α=2. When plotting 
these profiles, it was demonstrated that the duodenal samples 
of PARP1+/+ and PARP1‑/‑ animals were slightly different in 
terms of their diversity profiles (Fig. 1A and D; P<0.001 and 
P<0.01, respectively). Notably, on the species level the samples 
from PARP1‑/‑ demonstrated higher diversity values while 
on order level this trend was the opposite. When comparing 
diversity profiles representing the lower gastrointestinal tract 
(cecum) and feces, the only significant differences were in the 
cecal samples on order level (P<0.05; Fig. 1E). However, even 
in that case, although statistically significant, profile curves 
were very similar. The same trend was also demonstrated by 
the traditional Shannon and Simpson indices (Table I).
The most abundant orders in all samples were then 
investigated. Clostridiales and Bacteroidales represented 
between ~70 and 90% of all taxa across all samples. The less 
abundant orders were Lactobacillales, Erysipelotrichales and 
Verrucomicrobiales accounting for a further 5‑15% while the 
rest (~5‑15%) were spread out almost evenly between a further 
~30 orders (Fig. 2). On the order level all samples appeared to 
be similar, the only trend worth noting was the decreased ratio 
of Clostridiales in cecal and fecal samples when compared 
with duodenal ones (Fig. 2, middle panel). The statistical 
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significance levels are presented in Table II. This was true for 
samples from wild type and from PARP1‑/‑ animals, albeit the 
duodenal samples from the latter demonstrated a higher ratio of 
Clostridiales (~63% in PARP1‑/‑ animals vs. ~44% in PARP1+/+ 
animals; Fig. 2A). As these results indicated, the majority of 
the other orders proportionally advanced to fill in the gap left 
by Clostridiales throughout the gastrointestinal system.
Further investigation on the family level revealed that 
there was little to no difference in the main composition in 
Clostridiales (Fig. 2, right‑hand panel). The main families 
were Lachnospiraceae, Clostridiaceae, Eubacteriaceae 
and Ruminococcaceae. More than half of the Clostridiales 
were comprised of members of the Lachnospiraceae 
family (54‑65%), while the next two, Clostridiaceae and 
Ruminococcaceae, were responsible for a further ~20%. When 
comparing the family composition of the different samples, 
there was little to no changes in these ratios throughout the 
gastrointestinal system, nor were any differences detected 
between samples from wild type and PARP1‑/‑ animals, except 
for a slight elevation of the Ruminococcaceae ratio in the fecal 
samples of PARP1‑/‑ animals (Fig. 2, right‑hand panel; Table II; 
P<0.05).
When investigating the family composition of the 
order Bacteroidales the most abundant species were 
Porphyromonadaceae representing ~50‑90% of all taxa (Fig. 2, 
left‑hand panel). The other families included Rikenellaceae, 
Bacteroidaceae and Prevotellaceae. Other taxa not including 
those already mentioned reached only a combined ratio of 
a maximal 0.20% across all samples. PARP1‑/‑ originated 
samples demonstrated little change throughout the gastroin-
testinal system. The most noteworthy was the ~14% decrease 
in the family Porphyromonadaceae's ratio, which was almost 
exclusively made up for by the increase in Prevotellaceae and 
Bacteroidaceae between the duodenal and fecal samples. This 
Figure 1. Absence of PARP1 reduces microbial diversity. (A‑C) Species and (D‑F) order profiles in the different parts of the gastrointestinal tract tested, 
including the (A and D) duodenum, (B and E) cecum and (C and F) feces based on the Rényi index. PARP1, poly(adenosine diphosphate‑ribose) polymerase 1. 
*P<0.05, **P<0.01 and ***P<0.001 vs. PARP1+/+.
Table I. Simpson and Shannon indices obtained in the present study. 
 Species Order
 ---------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
Indices Duodenum Cecum Feces Duodenum Cecum Feces
PARP1 +/+ ‑/‑ +/+ ‑/‑ +/+ ‑/‑ +/+ ‑/‑ +/+ ‑/‑ +/+ ‑/‑
Simpson 0.883 0.948 0.955 0.933 0.942 0.931 0.651 0.528 0.726 0.693 0.710 0.727
Shannon 3.378 3.789 3.858 3.733 3.656 3.643 1.360 1.046 1.570 1.477 1.533 1.617
PARP1, poly(adenosine diphosphate‑ribose) polymerase 1.
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Figure 2. Composition of the bacterial flora changes on order and family ranks in the absence of PARP1. The ratio of the most abundant orders, as indicated in 
the middle pie charts and the family composition of the two most occurring families: Bacteroidales (left‑hand panel, bar charts) and Clostridiales (right‑hand 
panel, bar charts) for (A) duodenal, (B) cecal and (C) fecal samples. Microbiome taxon composition was created using the metagenomics RAST server, 
MG‑RAST, and taxon lists, and were analyzed using PAST and Taxamat. PARP1, poly(adenosine diphosphate‑ribose) polymerase 1.
Table II. Taxon proportion significance levels between compared samples.
 Significance levels
 ---------------------------------------------------------------------------------------------------------------------------
Compared samples Order Bacteroidales Clostridiales
PARP+/+ duodenum vs. PARP+/+ cecum P<0.05 P<0.001 ns
PARP+/+ duodenum vs. PARP+/+ feces P<0.001 P<0.001 ns
PARP+/+ cecum vs. PARP+/+ feces ns P<0.001 ns
PARP‑/‑ duodenum vs. PARP‑/‑ cecum P<0.001 P<0.01 ns
PARP‑/‑ duodenum vs. PARP‑/‑ feces P<0.001 P<0.01 ns
PARP‑/‑ cecum vs. PARP‑/‑ feces ns P<0.05 ns
PARP+/+ duodenum vs. PARP‑/‑ duodenum P<0.001 P<0.001 ns
PARP+/+ cecum vs. PARP‑/‑ cecum ns P<0.001 ns
PARP+/+ feces vs. PARP‑/‑ feces ns P<0.001 P<0.05
ns, non‑significant; PARP1, poly(adenosine diphosphate‑ribose) polymerase 1.
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14% decrease in the ratio of Porphyromonadaceae was much 
less prominent in PARP‑/‑ animals than in their PARP1+/+ coun-
terpart, where a 46 and 40% decrease was detected in cecal 
and fecal samples respectively, when compared with duodenal 
samples. In fact, the little change of Porphyromonadaceae in 
PARP1‑/‑ animals kept this family the most abundant one in the 
Bacteroidales order of the knockout strain across all samples, 
while in wild type animals only the duodenal samples were 
dominated (92%) by Porphyromonadaceae (Fig. 2A, left‑hand 
panel). Cecal and fecal samples in the PARP1+/+ group, 
consisted only 46 and 51% of Porphyromonadaceae respec-
tively (Fig. 2B and C, left‑hand panel; statistical significance 
levels are provided in Table II).
Samples isolated from wild type animals demonstrated 
notable changes too. Duodenal samples harbored ~92% 
Porphyromonadaceae in the order Bacteroidales, leaving 
barely any room for the other families in this order, the second 
most abundant being Prevotellaceae (3.6%) followed by 
Rikenellaceae (2.1%). Notably, Porphyromonadaceae contrib-
uted to only ~50% of the Bacteroidales family, while the other 
most prominent families indicated a ~10‑fold increase when 
compared with duodenal samples (Bacteroidaceae: 13‑17%; 
Prevotellaceae: 21‑29%; Fig. 2A‑C, statistical significance 
levels are provided in Table II).
Discussion
A recent study demonstrated PARP1‑mediated changes in the 
fecal microbiome in regard to mucosal injury (47). Following 
that thread, the composition of the microbiome on the lower 
part of the gastrointestinal tract and feces was assessed in the 
present study.
The most prominent result of the present study was that 
in the duodenum, in the absence of PARP1, the order of 
diversity decreased. These results were similar to those of 
Larmonier et al (47) who also reported a decrease in diversity.
Reference strains of mouse gut bacteria are practically 
unavailable and very few studies have attempted to provide 
a broad overview. One of these attempts was made in 2016 
by Lagkouvardos et al (48) who aimed to establish the Mouse 
Intestinal Bacterial Collection. Their results demonstrated 
that certain species are specific to the mouse intestine. The 
present results are based on direct sequencing only, while 
Lagkouvardos et al (48) utilized culturing in parallel. Despite 
the differences in methodology, the present results on order 
and family level are very similar with the ones mentioned in 
Lagkouvardos et al (48), thus validating them.
It is of note that the present experimental system did not 
challenge the microbiome; in other words, the absence of 
PARP1 alone led to visible changes in the microbiome in the 
absence of a disease. Furthermore, direct sequencing of 16S 
ribosomal DNA was used, which may add a bias to the chem-
istry prior to the in silico evaluation as compared with shotgun 
sequencing; however, in the upper parts of the gastrointestinal 
tract the number of the bacterial DNA is low as compared with 
the host DNA making shotgun sequencing cumbersome (20).
What could cause these changes in the microbiome? Innate 
immunity is already implicated in the regulation of gut bacteria 
through TLRs (22‑24). PARP1 is a positive co‑factor of several 
key inflammatory transcription factors (such as NF‑κB and 
activator protein‑1) (6) and through that PARP1 may modu-
late TLR function (36,37,40,49). Although, there is no direct 
evidence, the present study proposed that the interdependence 
of PARP1 and TLRs is a likely explanation for changes in the 
microbiome in the PARP1‑/‑ mice. PARP1 is responsible for 
the majority of the cellular PARP activity (5,50,51), therefore, 
its absence often resembles to PARP inhibitor treatment. 
However, there is no evidence for the capability of PARP 
inhibitors to influence the microbiome.
At present it is difficult to assess the physiological relevance 
of these findings. A body of evidence has indicated that 
PARP1 serves a key role in inflammatory pathologies [such as 
arthritis (52,53) or type I diabetes (54,55)] or metabolic diseases 
[such as type II diabetes (56‑58)], where the microbiome has a 
pivotal pathogenic role (26,57,58). Similarly to these, changes 
in the duodenal flora serve a dominant role in the pathogenesis 
of type II diabetes (59). These possibilities require further 
assessment in order to verify causal association. Damage to 
the gut flora, similarly to certain antibiotics, may contribute to 
the diarrhea observed as a side effect of PARP inhibitor treat-
ment in humans (60). This link between diarrhea and changes 
in the microbiome also suggests that the application of PARP 
inhibitors may predispose to or aggravate antibiotic‑induced 
diarrhea in PARP inhibitor‑treated patients. Taken together, 
understanding the link between PARPs and the microbiome has 
importance for the clinical application of these inhibitors.
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